Mazal CB
Angel Investor
Mazal CB is a seed investor focused on Health Care and Therapeutics. Mazal CB
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Mazal CB invests in
Stages Mazal CB invests in
Countries Mazal CB invests in
Investment Focus
Industry
- Health Care 1 (50%)
- Therapeutics 1 (50%)
- Medical Device 1 (50%)
- Personal Health 1 (50%)
- Health Diagnostics 1 (50%)
Stage
- Seed 1 (50%)
- Pre-Seed 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
DermaDetect
|
DermaDetect was co-founded a year ago by four experienced entrepreneurs and is clinically led by Prof. Arieh Ingber, former head of department of dermatology in Hadassa Medical Center in Israel, a world-renowned dermatologist.We've developed a diagnostics & treatment tool/app (Apple, Android, Web), which enables healthcareprofessionals and patients to self-triage & manage skin disorders. The underlying technology is based on the combination of two approaches: dermatological rule base inference & image analysis using machine learning.We’re in a progress of a pilot-study to validate the effectiveness of our technology within the Israeli Health system, which is world’s best sandbox for such a study.Funded by two angel investors, eHealth Ventures [and their partners: Maccabi Healthcare Services in Israel (second biggest HMO in Israel), the Cleveland Clinic (the second largest healthcare provider in the US), Amgen], and supported by the Israel Innovation Authority. | $800K / Seed / Aug 01, 2017 | |
|
DermaDetect
|
DermaDetect was co-founded a year ago by four experienced entrepreneurs and is clinically led by Prof. Arieh Ingber, former head of department of dermatology in Hadassa Medical Center in Israel, a world-renowned dermatologist.We've developed a diagnostics & treatment tool/app (Apple, Android, Web), which enables healthcareprofessionals and patients to self-triage & manage skin disorders. The underlying technology is based on the combination of two approaches: dermatological rule base inference & image analysis using machine learning.We’re in a progress of a pilot-study to validate the effectiveness of our technology within the Israeli Health system, which is world’s best sandbox for such a study.Funded by two angel investors, eHealth Ventures [and their partners: Maccabi Healthcare Services in Israel (second biggest HMO in Israel), the Cleveland Clinic (the second largest healthcare provider in the US), Amgen], and supported by the Israel Innovation Authority. | $1.2M / Pre-Seed / Aug 01, 2017 |
Co-Investors
eHealth Ventures
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Mazal CB invest in?
Mazal CB invests primarily in Health Care, Therapeutics and Medical Device startups, most often at Seed and Pre-Seed stage. Most of the 2 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Mazal CB last invest?
The most recent investment recorded for Mazal CB closed in Aug 2017. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
